…
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Vor Biopharma is a clinical-stage cell therapy company developing engineered hematopoietic stem cell products intended to protect normal bone marrow while enabling successive targeted leukemia treatments; its lead program VOR33 targets resistance to CD33-directed agents. Long-term growth may be driven by clinical progress across its HSC editing platform, expansion to additional oncology targets, and potential partnerships or licensing to scale manufacturing, and investors may find the differentiated approach to combining cell therapy with targeted agents of interest.
The most important investment risks are clinical and regulatory uncertainty for first-in-human HSC editing programs, complex and costly manufacturing and scaling challenges, high cash burn, and the likely need for additional financing.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -695.98M | -116.91M | -117.86M | -92.09M | -68.90M |
| Net income | -695.98M | -116.91M | -117.86M | -90.77M | -68.78M |
| Selling general administrative | 50.11M | 27.88M | 31.72M | 28.87M | 21.49M |
| Selling and marketing expenses | - | - | 3.49M | - | - |
| Gross profit | - | -3.53M | -3.49M | - | - |
| Reconciled depreciation | 2.89M | 3.53M | 3.23M | 2.52M | 1.43M |
| Ebit | -695.98M | -116.91M | -117.86M | -93.42M | -69.02M |
| Ebitda | -693.09M | -113.39M | -114.37M | -90.89M | -67.58M |
| Depreciation and amortization | 2.89M | 3.53M | 3.49M | 2.52M | 1.43M |
| Non operating income net other | - | - | - | 1.32M | 0.12M |
| Operating income | -371.64M | -121.19M | -126.04M | -93.42M | -69.02M |
| Other operating expenses | 371.64M | 121.19M | 126.04M | 93.42M | 69.02M |
| Interest expense | - | - | - | 1.32M | 1.55M |
| Interest income | 5.87M | 4.27M | 7.12M | 1.32M | 0.12M |
| Net interest income | 5.87M | 4.27M | 7.12M | 1.32M | 0.12M |
| Income tax expense | - | - | - | -1.32M | -0.12M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 371.64M | 121.19M | 122.54M | 93.42M | 69.02M |
| Cost of revenue | - | 3.53M | 3.49M | - | - |
| Total other income expense net | -324.34M | 4.27M | 8.17M | 1.32M | 0.12M |
| Net income from continuing ops | -695.98M | -116.91M | -115.51M | -92.09M | -68.90M |
| Net income applicable to common shares | - | - | - | -92.09M | -70.13M |
| Preferred stock and other adjustments | - | - | - | - | 1.23M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 464.13M | 142.89M | 209.83M | 299.37M | 242.59M |
| Other current assets | 2.90M | 4.58M | 3.63M | 2.34M | 2.09M |
| Total liab | 628.44M | 46.23M | 59.10M | 48.76M | 26.33M |
| Total stockholder equity | -164.31M | 96.66M | 150.72M | 250.61M | 216.26M |
| Other current liab | 19.76M | 12.89M | 10.93M | 8.07M | 0.43M |
| Common stock | 0.02M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.02M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -1152.97M | -456.99M | -340.08M | -222.22M | -130.12M |
| Other assets | - | - | - | 5.34M | 5.67M |
| Cash | 396.49M | 81.95M | 31.36M | 57.71M | 119.80M |
| Total current liabilities | 25.17M | 18.61M | 15.57M | 13.12M | 10.15M |
| Current deferred revenue | - | - | - | - | 6.33M |
| Net debt | -393.49M | -50.12M | 4.30M | -18.79M | -101.79M |
| Short term debt | 0.28M | 4.21M | 3.83M | 3.27M | 1.84M |
| Short long term debt total | 3.00M | 31.83M | 35.66M | 38.91M | 18.01M |
| Other stockholder equity | 988.60M | 553.62M | 490.87M | 473.59M | 346.38M |
| Property plant equipment | - | - | - | 12.63M | 6.85M |
| Total current assets | 458.11M | 96.51M | 140.80M | 236.95M | 214.40M |
| Net tangible assets | - | - | - | 250.61M | 216.26M |
| Short term investments | 58.72M | 9.98M | 105.81M | 172.54M | 87.67M |
| Accounts payable | 5.13M | 1.50M | 0.81M | 1.77M | 1.54M |
| Accumulated other comprehensive income | 0.04M | 0.02M | -0.08M | -0.77M | -242.59M |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Retained earnings total equity | - | - | - | -222.22M | -130.12M |
| Non currrent assets other | 2.55M | 4.80M | 4.81M | 5.34M | 5.67M |
| Non current assets total | 6.02M | 46.38M | 69.03M | 62.42M | 28.19M |
| Capital lease obligations | 3.00M | 31.83M | 35.66M | 38.91M | 18.01M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -48.66M | 96.86M | -36.36M | -85.63M | -87.76M |
| Change to liabilities | - | - | - | 1.11M | 0.41M |
| Total cashflows from investing activities | -48.80M | 96.86M | 71.01M | -94.09M | -91.65M |
| Total cash from financing activities | 503.81M | 53.39M | 2.94M | 117.14M | 232.91M |
| Change to operating activities | - | - | - | -13.81M | -9.59M |
| Net income | -695.98M | -116.91M | -117.86M | -92.09M | -68.90M |
| Change in cash | 312.29M | 50.59M | -26.35M | -62.09M | 72.12M |
| Begin period cash flow | 84.36M | 33.77M | 60.12M | 122.21M | 50.10M |
| End period cash flow | 396.65M | 84.36M | 33.77M | 60.12M | 122.21M |
| Total cash from operating activities | -142.71M | -99.66M | -100.29M | -85.14M | -69.14M |
| Issuance of capital stock | 328.21M | 55.83M | 116.22M | 115.97M | 234.57M |
| Depreciation | 2.89M | 3.53M | 3.49M | 2.52M | 1.43M |
| Other cashflows from investing activities | 0.80M | - | - | - | - |
| Sale purchase of stock | - | - | -1.19M | 4.45M | 187.54M |
| Other cashflows from financing activities | -1.32M | -2.43M | -1.64M | 1.17M | 43.71M |
| Change to netincome | - | - | - | 10.68M | 4.49M |
| Capital expenditures | 0.94M | 0.23M | 1.07M | 8.46M | 3.89M |
| Cash flows other operating | - | - | - | -7.37M | -6.57M |
| Cash and cash equivalents changes | - | - | - | -62.09M | 72.12M |
| Change in working capital | 10.21M | 0.01M | 0.65M | -12.69M | -9.19M |
| Stock based compensation | 18.91M | 9.85M | 13.36M | 10.70M | 4.32M |
| Other non cash items | 521.26M | 3.87M | 0.07M | 6.42M | 3.19M |
| Free cash flow | -143.65M | -99.89M | -101.36M | -93.61M | -73.04M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma Inc |
0.67 3.62% |
19.19 | 0.13 | - | - | 0.66 | -3.09 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Robert Ang M.B.A., M.D., MBBS | Pres, CEO & Director | 1975 |
| Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer | 1973 |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder & Chairman of Scientific Advisory Board | 1971 |
| Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer | 1977 |
| Ms. Tania Philipp | Chief People Officer | 1972 |
| Dr. Robert G. Pietrusko Pharm.D., Pharm. D. | Chief Regulatory & Quality Officer | 1948 |
| Mr. John C. King M.B.A. | Chief Commercial Officer | 1976 |
| Dr. Veit Schmelmer Ph.D. | Sr. VP of Program & Alliance Management | NA |
| Dr. Eyal C. Attar M.D. | Chief Medical Officer | 1971 |
| Dr. Robert Ang M.B.A., M.D., MBBS | President, CEO & Director | 1975 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.